These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33418558)

  • 1. CRISPR/Cas9 mediated knock-out of VPREB1 gene induces a cytotoxic effect in myeloma cells.
    Khaled M; Moustafa AS; El-Khazragy N; Ahmed MI; Abd Elkhalek MA; El Salahy EM
    PLoS One; 2021; 16(1):e0245349. PubMed ID: 33418558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic status and the prospect of CRISPR/Cas9 gene editing in multiple myeloma.
    Hong L; Zhang C; Jiang Y; Liu H; Huang H; Guo D
    Future Oncol; 2020 Jun; 16(16):1125-1136. PubMed ID: 32338048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of mouse and human preimplantation development following POU5F1 CRISPR/Cas9 targeting reveals interspecies differences.
    Stamatiadis P; Boel A; Cosemans G; Popovic M; Bekaert B; Guggilla R; Tang M; De Sutter P; Van Nieuwerburgh F; Menten B; Stoop D; Chuva de Sousa Lopes SM; Coucke P; Heindryckx B
    Hum Reprod; 2021 Apr; 36(5):1242-1252. PubMed ID: 33609360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas9 system: A new-fangled dawn in gene editing.
    Gupta D; Bhattacharjee O; Mandal D; Sen MK; Dey D; Dasgupta A; Kazi TA; Gupta R; Sinharoy S; Acharya K; Chattopadhyay D; Ravichandiran V; Roy S; Ghosh D
    Life Sci; 2019 Sep; 232():116636. PubMed ID: 31295471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of Knocking Out
    Man JC; Cheng J; Zhao L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):52-56. PubMed ID: 38387899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 mediated GFP-human dentin matrix protein 1 (DMP1) promoter knock-in at the ROSA26 locus in mesenchymal stem cell for monitoring osteoblast differentiation.
    Shahabipour F; Oskuee RK; Shokrgozar MA; Naderi-Meshkin H; Goshayeshi L; Bonakdar S
    J Gene Med; 2020 Dec; 22(12):e3288. PubMed ID: 33047833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-Mediated Knock-Out of Kras
    Lentsch E; Li L; Pfeffer S; Ekici AB; Taher L; Pilarsky C; Grützmann R
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.
    Bexte T; Alzubi J; Reindl LM; Wendel P; Schubert R; Salzmann-Manrique E; von Metzler I; Cathomen T; Ullrich E
    Oncoimmunology; 2022; 11(1):2081415. PubMed ID: 35694192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR based targeted genome editing of Chlamydomonas reinhardtii using programmed Cas9-gRNA ribonucleoprotein.
    Dhokane D; Bhadra B; Dasgupta S
    Mol Biol Rep; 2020 Nov; 47(11):8747-8755. PubMed ID: 33074412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of surrogate light chain in tetrapods and the relationship between lengths of CDR H3 and VpreB tails.
    Ott JA; Haakenson JK; Kelly AR; Christian C; Criscitiello MF; Smider VV
    Front Immunol; 2022; 13():1001134. PubMed ID: 36311706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-mediated gene editing. A promising strategy in hematological disorders.
    Ugalde L; Fañanas S; Torres R; Quintana-Bustamante O; Río P
    Cytotherapy; 2023 Mar; 25(3):277-285. PubMed ID: 36610813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent developments in enhancing the efficiency of CRISPR/Cas9- mediated knock-in in animals].
    Li GL; Yang SX; Wu ZF; Zhang XW
    Yi Chuan; 2020 Jul; 42(7):641-656. PubMed ID: 32694104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells.
    Kamali E; Rahbarizadeh F; Hojati Z; Frödin M
    BMC Biotechnol; 2021 Jan; 21(1):9. PubMed ID: 33514392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical non-viral vectors exploited for
    Rouatbi N; McGlynn T; Al-Jamal KT
    Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in therapeutic application of CRISPR-Cas9.
    Sun J; Wang J; Zheng D; Hu X
    Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research and Therapeutic Approaches in Stem Cell Genome Editing by CRISPR Toolkit.
    Mollashahi B; Latifi-Navid H; Owliaee I; Shamdani S; Uzan G; Jamehdor S; Naserian S
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNPs and real-time quantitative PCR method for constitutional allelic copy number determination, the VPREB1 marker case.
    Frigerio M; Passeri E; de Filippis T; Rusconi D; Valaperta R; Carminati M; Donnangelo A; Costa E; Persani L; Finelli P; Corbetta S
    BMC Med Genet; 2011 May; 12():61. PubMed ID: 21545739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.